The shares of Biontech and Moderna crashed

The shares of Biontech and Moderna crashed yesterday - and are making up at least a small part of the losses today. Expressed in numbers: Biontech crashed almost 14 percent, Moderna around 15 percent. The papers from Biontech partner Pfizer lost almost 4 percent of their value. Biontech is still up 3.1 percent today, Moderna 1.8 percent before it goes public in the USA. Pfizer is trending unchanged. When things went downhill yesterday, people on the stock exchanges rubbed their eyes in amazement and then found an explanation: The European Medicines Agency (EMA) is examining whether rare symptoms that have occurred after the administration of mRNA vaccines against Covid-19 should be classified as a side effect. Biontech and Moderna have developed their Covid vaccines based on this technology. The responsible safety committee is dealing with reports of one form of allergic skin reaction and two kidney conditions that have occurred in small groups of people, according to the EMA. Or maybe the news was just a welcome opportunity to take profits. Because since the beginning of the year, the papers from Biontech have increased a whopping 313 percent. The success of the Mainz-based biopharmaceutical company with its corona vaccine is not only driving the share price, but also economic growth in Germany. "Biontech could contribute around 0.5 percent to the gross domestic product this year," says the Scientific Director of the Institute for Macroeconomics and Business Cycle Research (IMK), Sebastian Dullien. "Economic growth should also increase by around half a point as a result." Many experts believe that Europe's largest economy will grow by around four percent this year, of which about one eighth is attributable to Biontech alone.